HSP90: A potential drug target in inflammatory skin diseases

Abstract

AbstractHeat shock protein 90 (HSP90) is a chaperone protein belonging to the HSP family. HSP90 modulates clients by stabilising, folding, maturing, and tagging clients for proteasomal degradation. Several clients of HSP90 are involved in cancer development and HSP90 is required for some oncoproteins, making HSP90 a potential target in anticancer treatment. Recently HSP90 has also been suggested as a potential drug target in inflammatory skin diseases based on both in vitro and in vivo studies in animal models and human clinical trials. The role of HSP90 in blistering skin diseases has been studied in vitro, ex vivo, and in vivo using animal models. Human clinical studies investigating HSP90 inhibition in psoriasis and hidradenitis suppurativa have either been conducted or are ongoing and in vitro and ex vivo studies have investigated the role of HSP90 in systemic lupus erythematosus and diffuse cutaneous systemic sclerosis. Here, we review the current literature investigating the role of HSP90 in these diseases.